BeOne Medicines presents additional oncology data at ESMO 2026, including 36% response rate for GPC3 x 4-1BB bispecific in liver cancer

BeOne Medicines presented new data from multiple investigational medicines at the ESMO Congress 2026 in Madrid. Findings included a 36% confirmed response rate for a potential first-in-class GPC3 x 4-1BB bispecific in heavily pretreated liver cancer, plus durable survival benefits for TEVIMBRA plus ZIIHERA in first-line HER2-positive gastroesophageal adenocarcinoma.

Detected & updated continuously · Source: Nebula